Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors

SAN DIEGO May 24, 2016 – Amplyx Pharmaceuticals today announced the appointment of Paul C. Grint, M.D., to its Board of Directors. Dr. Grint, president and CEO, Regulus Therapeutics, joined Regulus in June 2014 as Chief Medical Officer.  Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology therapeutic areas.

“Paul is an essential new addition to our Board of Directors, with his wealth of experience in drug development in the anti-infectives space,” said Mike Grey, President and CEO of Amplyx Pharmaceuticals. “His insights will be invaluable as we move APX001 into clinical development studying serious fungal infections caused by Candida and Aspergillus, as well as rare, difficult-to-treat molds.”

APX001 is a novel small molecule with a unique mechanism of action. In preclinical studies, the compound showed broad-spectrum activity against infections caused by common species of Candida and Aspergillus, as well as good activity against rare molds. Patients with compromised immune systems due to chemotherapy or other immune-compromising medical treatments are susceptible to these potentially deadly fungal infections. Amplyx is developing both IV and oral formulations of APX001 to address the need for hospital administration, as well as continued dosage after hospital discharge.

“Amplyx has a great combination of a seasoned, successful management team, and a promising drug candidate in a space where there is significant unmet medical need,” said Dr. Grint. “It is a pleasure to work with the Amplyx team, and I look forward to advising on clinical development and possible future commercialization of APX001 through my board position.”

About Amplyx Pharmaceuticals

Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The company’s lead compound, APX001, is expected to enter clinical development in 2016 and has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. Amplyx has raised $51.5 million in venture capital and received more than $10 million in grants from the National Institutes of Health to support its drug discovery and development efforts. The company’s research operations are located at Johnson & Johnson Innovation, JLABS in San Diego, Calif.

Contact:

Heidi Chokeir, Ph.D.
Senior Vice President
Canale Communications
(619) 849-5377
heidi@canalecomm.com